Abuse-Deterrent Opioids: Generics Worry Comparator Standard Impedes Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's draft guidance could make it difficult for generics to show abuse deterrence, especially given 'moving target' of innovator labeling changes, generic firms say.